Sandbox:Mydah: Difference between revisions
MydahSajid (talk | contribs) |
MydahSajid (talk | contribs) |
||
Line 22: | Line 22: | ||
*[[Methyldopa]]<ref name="pmid1268617">{{cite journal| author=Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A| title=Effects of methyldopa on prolactin and growth hormone. | journal=Br Med J | year= 1976 | volume= 1 | issue= 6019 | pages= 1186-8 | pmid=1268617 | doi=10.1136/bmj.1.6019.1186 | pmc=1639736 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1268617 }} </ref> | *[[Methyldopa]]<ref name="pmid1268617">{{cite journal| author=Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A| title=Effects of methyldopa on prolactin and growth hormone. | journal=Br Med J | year= 1976 | volume= 1 | issue= 6019 | pages= 1186-8 | pmid=1268617 | doi=10.1136/bmj.1.6019.1186 | pmc=1639736 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=1268617 }} </ref> | ||
*[[Verapamil]] | *[[Verapamil]] | ||
* Familial [[hyperprolactinemia]] | * Familial [[hyperprolactinemia]]<ref name="pmid24195502">{{cite journal| author=Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M | display-authors=etal| title=Mutant prolactin receptor and familial hyperprolactinemia. | journal=N Engl J Med | year= 2013 | volume= 369 | issue= 21 | pages= 2012-2020 | pmid=24195502 | doi=10.1056/NEJMoa1307557 | pmc=4209110 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24195502 }} </ref> | ||
*[[Hypothyroidism]] | *[[Hypothyroidism]] | ||
*[[Chronic renal failure]] | *[[Chronic renal failure]] |
Revision as of 19:38, 10 August 2020
Associate Editor(s)-in-Chief: Mydah Sajid, MD[1]
Hyperprolactinemia resident survival guide
Overview
Hyperprolactinemia is defined as high circulating levels of prolactin in the blood. The cut-off values of serum prolactin for hyperprolactinemia are greater than 20 ng/ml in men and postmenopausal women and greater than 30ng/ml in premenopausal women.[1] Prolactin hormone is produced by lactotroph cells located in the anterior lobe of the pituitary gland. It is responsible for lactation and the development of breasts in females during pregnancy. Elevated levels of prolactin cause galactorrhea, menstrual irregularities, and failure to conceive in females and erectile dysfunction, hypogonadism, and infertility in males. This section provides a short and straight to the point overview of the hyperprolactinemia.
Causes
Life-threatening Causes
Life-threatening causes include conditions that may result in death or permanent disability within 24 hours if left untreated.
- Severe burns on the chest can cause hyperprolactinemia due to neural stimulation similar to suckling[2].
Common Causes
- Pregnancy[3]
- Lactation[3]
- Prolactinoma[4]
- Injury to dopaminergic neurons in the hypothalamus (sarcoidosis, craniopharyngioma, and metastatic brain carcinoma)[4]
- Section of the hypothalamic-pituitary stalk
- Antipsychotics (risperidone, haloperidol, and phenothiazine)[5]
- Selective serotonin reuptake inhibitors
- Metoclopramide[6]
- Domperidone[7]
- Methyldopa[8]
- Verapamil
- Familial hyperprolactinemia[9]
- Hypothyroidism
- Chronic renal failure
- macroprolactinomas
- Exercise
Evaluation
Shown below is an algorithm summarizing the diagnosis of hyperprolactinemia according to an Endocrine Society Clinical Practice guidelines[1][10]:
Characterize the symptoms
| |||||||||||||||||||||||
Inquire about any present illness like hypothyroidism, chronic renal failure, and the use of medications known to cause hyperprolactinemia. | |||||||||||||||||||||||
Measure serum prolactin. Elevated serum prolactin | |||||||||||||||||||||||
Mesure serum TSH. TSH levels elevated? | |||||||||||||||||||||||
Yes | No | ||||||||||||||||||||||
Treat hypothyroidism | Perform the MRI with the contrast of the brain. Does it show any mass in the hypothalamic-pituitary region? | ||||||||||||||||||||||
Levels of TSH and prolactin should be reassessed after 6-12 weeks. | Yes. The levels of other pituitary hormones should be evaluated: Plasma corticotropins (ACTH), Serum TSH, Insulin-like growth factors, Follicle-stimulating hormone, Luteinizing hormone, Estradiol/ Testosterone | No | |||||||||||||||||||||
Management
Shown below is an algorithm summarizing the treatment of hyperprolactinemia:
The prolactinoma are treated in the following patients:
| |||||||||||||||||||||
The drug of choice for prolactinoma are dopamine agonists as they decrease prolactin secretion and reduce the size of the prolactinoma. Cabergoline is the preferred drug because of its efficacy and lower incidence of nausea and side effects compared to bromocriptine. | Transsphenoidal surgery is done in:
| ||||||||||||||||||||
The preferred initial dose of cabergoline for microadenoma is 0.25mg twice a week or 0.5mg once a week. The medicine should be given at dinner or bedtime to reduce the incidence of nausea and drowsiness. | Transsphenoidal surgery has a high success rate in reducing serum prolactin to a normal level. | ||||||||||||||||||||
Do's
- “Hook effect” should be kept in consideration while assessing serum prolactin levels. Patients with macroadenoma can have artifactually low values of serum prolactin between 20 to 200 mcg/L in patients with high levels of serum prolactin i.e. 5000 mcg/L. This artifact is avoided by repeating the assay by dilution of serum.
- Cabergoline is preferred by women who wish to conceive as it is safe in early pregnancy. Though bromocriptine is also a safe choice with more evidence of reduced events of congenital defects.
- Patients with hyperprolactinemia with normal serum prolactin levels should be monitored for regular intervals after discontinuing cabergoline. There is a recurrence of hyperprolactinemia in these patients.
Don'ts
- Certain medications like risperidone, domperidone, methyldopa, metoclopramide, verapamil, and cimetidine raise serum prolactin levels. These medications can blunt the effects of dopamine agonists.
- The patients should be monitored for side effects. Cabergoline treatment in prolactinoma patients for more than three months can result in impulse control disorders. Hypersexuality is common in males and compulsive eating disorders in females.
References
- ↑ 1.0 1.1 Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA; et al. (2011). "Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline". J Clin Endocrinol Metab. 96 (2): 273–88. doi:10.1210/jc.2010-1692. PMID 21296991.
- ↑ Morley JE, Dawson M, Hodgkinson H, Kalk WJ (1977). "Galactorrhea and hyperprolactinemia associated with chest wall injury". J Clin Endocrinol Metab. 45 (5): 931–5. doi:10.1210/jcem-45-5-931. PMID 562902.
- ↑ 3.0 3.1 Tyson JE, Hwang P, Guyda H, Friesen HG (1972). "Studies of prolactin secretion in human pregnancy". Am J Obstet Gynecol. 113 (1): 14–20. doi:10.1016/0002-9378(72)90446-2. PMID 5024994.
- ↑ 4.0 4.1 Kleinberg DL, Noel GL, Frantz AG (1977). "Galactorrhea: a study of 235 cases, including 48 with pituitary tumors". N Engl J Med. 296 (11): 589–600. doi:10.1056/NEJM197703172961103. PMID 840242.
- ↑ David SR, Taylor CC, Kinon BJ, Breier A (2000). "The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia". Clin Ther. 22 (9): 1085–96. doi:10.1016/S0149-2918(00)80086-7. PMID 11048906.
- ↑ McCallum RW, Sowers JR, Hershman JM, Sturdevant RA (1976). "Metoclopramide stimulates prolactin secretion in man". J Clin Endocrinol Metab. 42 (6): 1148–52. doi:10.1210/jcem-42-6-1148. PMID 777023.
- ↑ Sowers JR, Sharp B, McCallum RW (1982). "Effect of domperidone, an extracerebral inhibitor of dopamine receptors, on thyrotropin, prolactin, renin, aldosterone, and 18-hydroxycorticosterone secretion in man". J Clin Endocrinol Metab. 54 (4): 869–71. doi:10.1210/jcem-54-4-869. PMID 7037817.
- ↑ Steiner J, Cassar J, Mashiter K, Dawes I, Fraser TR, Breckenridge A (1976). "Effects of methyldopa on prolactin and growth hormone". Br Med J. 1 (6019): 1186–8. doi:10.1136/bmj.1.6019.1186. PMC 1639736. PMID 1268617.
- ↑ Newey PJ, Gorvin CM, Cleland SJ, Willberg CB, Bridge M, Azharuddin M; et al. (2013). "Mutant prolactin receptor and familial hyperprolactinemia". N Engl J Med. 369 (21): 2012–2020. doi:10.1056/NEJMoa1307557. PMC 4209110. PMID 24195502.
- ↑ Majumdar A, Mangal NS (2013). "Hyperprolactinemia". J Hum Reprod Sci. 6 (3): 168–75. doi:10.4103/0974-1208.121400. PMC 3853872. PMID 24347930.